Compare DCTH & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | OSUR |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.5M | 215.9M |
| IPO Year | 2015 | 2000 |
| Metric | DCTH | OSUR |
|---|---|---|
| Price | $11.13 | $3.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $22.00 | $3.00 |
| AVG Volume (30 Days) | 327.1K | ★ 397.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $167,064,000.00 |
| Revenue This Year | $24.54 | $4.48 |
| Revenue Next Year | $33.15 | $7.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $2.08 |
| 52 Week High | $18.23 | $3.76 |
| Indicator | DCTH | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 48.48 |
| Support Level | $10.17 | $2.87 |
| Resistance Level | $11.99 | $3.25 |
| Average True Range (ATR) | 0.54 | 0.13 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 54.50 | 35.74 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.